Evaluating Cell Reprogramming, Differentiation and Conversion Technologies in Neuroscience|
The scarcity of live human brain cells for experimental access has for a long time limited our ability to study complex human neurological disorders and elucidate basic neuroscientific mechanisms. A decade ago, the development of methods to reprogram somatic human cells into induced pluripotent stem cells enabled the in vitro generation of a wide range of neural cells from virtually any human individual. [Nat Rev Neurosci] Abstract
Visit our reviews page to see a complete list of reviews in the neural cell research field.
Seattle Children’s and Juno Therapeutics Accelerate T-Cell Immunotherapy Clinical Trials for Children and Adults with Deadly Brain Cancers|
Seattle Children’s announced that it has signed a letter of intent with Juno Therapeutics, Inc., to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors, known as gliomas. [Seattle Children’s Hospital] Press Release
Neurotrope Enters Into Research Collaboration with the International Rett Syndrome Foundation/Rettsyndrome.org
Neurotrope, Inc. announced that it has entered into a research collaboration with the International Rett Syndrome Foundation, DBA: Rettsyndrome.org, to explore the potential of Bryostatin for the treatment of Rett syndrome. [Neurotrope, Inc. (PR Newswire Association LLC.)] Press Release
BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase III Clinical Trial in Glioblastoma
BioLife Solutions, Inc. announced that through its biologistex joint venture, it will partner with MNX Global Logistics to support the registrational Phase III clinical trial being conducted by ImmunoCellular Therapeutics for their ICT-107 dendritic cell-based immunotherapy for newly diagnosed glioblastoma. [BioLife Solutions, Inc.] Press Release
DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase II Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme
DelMar Pharmaceuticals, Inc. announced the successful completion of an End of Phase II meeting with the U.S. Food and Drug Administration (FDA). [DelMar Pharmaceuticals, Inc.] Press Release
MJFF Supports Stem Cell Projects to Explore Therapies and Provide Research Tools
The Michael J. Fox Foundation (MJFF) announced funding for two projects leveraging the promise of engineered stem cells to speed new therapies and deeper understanding of Parkinson’s disease. [The Michael J. Fox Foundation] Press Release
From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture. Watch now.